12.03.2018
SHOP APOTHEKE EUROPE N.V. NL0012044747
DGAP-News: SHOP APOTHEKE EUROPE increases revenues by 60% in 2017; growth projected to further accelerate in 2018 with positive Group-level EBITDA expected.
DGAP-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): Final Results/Forecast
SHOP APOTHEKE EUROPE increases revenues by 60% in 2017; growth projected to
further accelerate in 2018 with positive Group-level EBITDA expected.
12.03.2018 / 06:59
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
NOT FOR RELEASE OT DISTRIBUTION IN THE USA, CANADA, AUSTRALIA OR JAPAN.
SHOP APOTHEKE EUROPE increases revenues by 60% in 2017; growth projected to
further accelerate in 2018 with positive Group-level EBITDA expected.
* In 2017 Group revenues rise by +60% to EUR 284 m.
* Leading market position in Germany and Continental Europe further
extended.
* Forecast 2018 I: range for revenue growth 87% to 97%.
* Forecast 2018 II: Positive Group-level EBITDA* of EUR 0 to 2 m
projected.
Venlo/Cologne, March 12, 2018. -- SHOP APOTHEKE EUROPE N.V., Continental
Europe's leading online pharmacy, has reached its ambitious growth targets
for the 2017 fiscal year (January 1 - December 31, 2017). Boosted by the
takeover of Europa Apotheek in November 2017, SHOP APOTHEKE EUROPE has
further accelerated its growth rate substantially with Group revenues rising
60% to EUR 284.0 m. For 2018 management expects the pace of growth to
further speed up to a rate of 87% to 97% as well as a positive Group-level
EBITDA* of EUR 0 to 2 m.
The company's dynamic growth is due to an increase in the number of active
customers across Europe from 1.8 m at the end of 2016 to approximately 2.7 m
at the end of 2017 and the related rise in the volume of orders. The number
of orders climbed from 4.0 m to 5.7 m during the period under review, with
76% of those orders coming from existing customers, up from an already high
level of 73% in 2016. The return rate stayed at a minimal level of below 1%
of orders like in 2016. The number of site visits increased from 41.8 m
during the 2016 fiscal year to 71.5 m in 2017.
Group revenues rose by 60% during the 2017 fiscal year to EUR 284.0 m from
EUR 177.4 m a year earlier. This increase in revenues is due to both organic
growth and to the fourth-quarter takeover of Europa Apotheek, which has been
consolidated as of November 8, 2017, accounting for EUR 25.1 m in revenues.
Gross earnings rose by 59% from EUR 36.3 m to EUR 57.6 m during the 2017
fiscal year, leading to a gross margin of 20.3% compared to 20.5% in 2016.
The slight decrease in the gross margin is mainly due to a higher proportion
of prescription medications sold as a result of the takeover of Europa
Apotheek; these usually have a lower gross margin than other products in the
portfolio.
Increases in efficiency and economies of scale contributed to a
substantially improved administrative expenses ratio. Total administrative
costs for 2017 were EUR 13.4 m compared to EUR 9.1 m in 2016. This figure
includes one-time costs of EUR 3.6 m related to the takeover of Europa
Apotheek and the subsequent increase in capital in order to process the
share swap agreed on to undertake the acquisition. Hence, adjusted
administrative expenses ratio including depreciations stood at 3.5% in
proportion to revenues (previous year: 4.2%).
Revenues for SHOP APOTHEKE EUROPE'S profitable core segment "Germany" rose
by 44% to EUR 209.5 m (previous year: EUR 145.5 m). During the same
timeframe, the overall German online pharmacy market grew by just 11.8%
according to a survey conducted by Germany's Federal Association for
e-commerce and mail order businesses (Bundesverband
E-Commerce und Versandhandel/bevh). Thus, SHOP APOTHEKE EUROPE has been able
to further extend its market leadership in Continental Europe's largest
online pharmacy market. Due to the bigger ratio of prescription medications
sold, the 2017 gross margin stood at 19.8% compared to 20.4% a year earlier.
Cost of sales grew at a lower rate than revenues, increasing 33% from EUR
27.5 m in 2016 to EUR 36.8 m in 2017. Accordingly, the sales cost ratio
improved to 17.6% for the reporting period compared to 18.8% the previous
year. Segment EBITDA** was EUR 6.9 m, up from EUR 4.0 m for the 2016 fiscal
year with a margin of 3.3% for the year under review compared to 2.7% in
2016.
SHOP APOTHEKE EUROPE'S international markets - which include Austria,
France, Belgium, the Netherlands, Spain and Italy - have been once again the
company's most dynamic driver of growth, with the volume of business
increasing by more than 143%. As a result, revenues for the "International"
segment rose to EUR 73.7 m (previous year: EUR 30.4 m) with the segment's
gross margin growing significantly during the period under review, up 3
percentage points to 21.4% from 18.4% a year earlier. Due to the high cost
of new customer acquisition, 2017 segment EBITDA** was EUR -6.6 m, down EUR
1.9 m compared to EUR -4.7 m the previous year (respectively EUR -4.0 m when
adjusted for one-time costs related to the acquisition of Farmaline in
2016). Relative to revenues, the segment's EBITDA margin improved to -8.9%
in the period under review compared to -15.6% unadjusted, or -13.0% adjusted
respectively in 2016.
The segment "Germany Services" posted revenues of EUR 0.7 m (previous year:
EUR 2.5 m) excluding sales revenues from intra-Group services that were
eliminated as part of the consolidation. Since it contributes only a small
share of overall revenues, the segment will be integrated into the "Germany"
segment in the future. At 88.4%, the gross margin was at a similarly high
level as in 2016 when it stood at 89.7%. Segment EBITDA** was EUR -0.1 m
compared to EUR 1.0 m a year earlier.
Dr. Ulrich Wandel, CFO of SHOP APOTHEKE EUROPE, comments on the company's
development during the 2017 fiscal year: "We have achieved our ambitious
growth targets with a revenue increase of 60%. Our accelerated growth course
is driven by strong operational results as well as key investment decisions.
The integration of Europa Apotheek has further strengthened our growth
trajectory. In 2018 we'll keep our foot on the accelerator. We want to
achieve an attractive combination of fast growth and profitability during
the current fiscal year."
For the 2018 fiscal year, SHOP APOTHEKE EUROPE's Management Board forecasts
a revenue increase between 87% and 97% to a range of EUR 530 to 560 m,
driven primarily by strong international growth and the consolidation of
Europa Apotheek. The gross margin is expected to be lower than during the
2017 fiscal year due to the greater proportion of orders for prescription
medications. Despite the smaller gross margin, the contribution margin per
order will be bigger due to the increase in the size of the average shopping
basket. Combined with further improvements in efficiency, effects of scale
and further automation, the Management Board forecasts a positive
Group-level EBITDA* of EUR 0 to 2 m for the 2018 fiscal year.
Brand strategy will be another focus during the coming year. As a result of
the acquisitions undertaken in the last two years, SHOP APOTHEKE EUROPE is
currently operating its business using several different brand names, which
will for the most part be united under a common brand in the medium term.
SHOP APOTHEKE EUROPE also plans to continue playing an active role in the
consolidation of the online pharmacy market. Due to both potential future
acquisitions and a generally greater need for working capital as a result of
increased business volume, the Management Board is evaluating different
financing models options that allow the company to respond flexibly and
quickly should interesting opportunities arise.
The investment volume for the current fiscal year is expected to be in the
low double-digit million range. Investments will focus on automation and
expanding storage capacity, the parallel optimization of our software
systems and the standardisation of payment methods across the Group in order
to standardise the checkout process for customer orders and further develop
our customer relations management across all country webshops.
* prior to special effects due to potential transactions and/or acquisitions
**Segment EBITDA defined as earnings before interest, taxes, deductions and
amortizations as well as Group-level administrative expenses.
2018 FINANCIAL CALENDAR
April 26, 2018 Annual General Meeting
May 15, 2018 Publication of the results of Q1 2018
August 14, 2018 Publication of the results of the first half of
2018
November 14, Publication of the results of Q3 2018
2018
CONSOLIDATED STATEMENT OF PROFIT AND LOSS.
PERIOD ENDED PERIOD ENDED
31.12.2017 31.12.2016
EUR 1,000 EUR 1,000
Revenue 283,992 177,391
Cost of sales -226,407 -141,109
Gross profit 57,585 36,282
Other income 3,015 2,204
Selling and distribution -66,417 -41,036
Administrative expensess -13,378 -9,098
Result from operations -19,197 -11,639
Finance income 40 17
Finance expenses -2,246 -9,338
Net finance costs -2,206 -9,321
Result before tax -21,403 -20,960
Income tax expenses 45 2,515
Result after tax -21,358 -18,445
Attributable to: -21,358 -18,445
Owners of the company
CONSOLIDATED SEGMENT FINANCIALS FOR 2017.
Germany Internat- German- Eliminat- Consolid-
ional y ions ated
Servic-
es
EUR EUR EUR EUR EUR
1,000 1,000 1,000 1,000 1,000
Revenue 209,549 73,716 6,848 -6,121 283,992
Cost of sales -168,04- -57,971 -797 401 -226,407
0
Gross profit 41,510 15,745 6,050 -5,720 57,585
% of revenue 19.80% 21.40% 88.40% 20.30%
Other income 2,151 810 54 0 3,015
Selling & distribution -36,801 -23,160 -6,176 5,720 -60,417
Adjusted S&D -36,801 -23,160 -6,176 -60,417
Segment EBITDA 6,859 -6,606 -71 0 182
Adjusted segment EBITDA 6,859 -6,606 -71 0 182
Administrative expenses -12,320
Adjusted AE -8,728
EBITDA -12,137
Adjusted EBITDA -8,545
Depreciation -7,059
EBIT -19,197
Adjusted EBIT -15,605
Net finance cost and -2,161
income tax
Adjusted net finance cost -2,161
and income tax
Net loss -21,358
Adjusted net loss -17,766
CONSOLIDATED SEGMENT FINANCIALS FOR 2016.
Germany Internat- German- Eliminat- Consolid-
ional y ions ated
Servic-
es
EUR EUR EUR EUR EUR
1,000 1,000 1,000 1,000 1,000
Revenue 145,549 30,376 4,108 -2,641 177,391
Cost of sales -115,91- -24,777 -423 0 -141,109
0
Gross profit 29,640 5,599 3,685 -2,641 36,282
% of revenue 20.40% 18.40% 89.70% 20.50%
Other income 1,810 363 31 0 2,204
Selling & distribution -27,458 -10,698 -2,742 2,641 -38,255
Adjusted S&D -27,419 -9,901 -2,742 2641 -37,421
Segment EBITDA 3,992 -4,735 975 231
Adjusted segment EBITDA 4,030 -3,939 975 1066
Administrative expenses -8,597
Adjusted AE -6,855
EBITDA -8,366
Adjusted EBITDA -5,789
Depreciation -3,273
EBIT -11,638
Adjusted EBIT -9,062
Net finance cost and -6,807
income tax
Adjusted net finance cost -1,644
and income tax
Result before tax -18,445
Adjusted net loss -10,733
ABOUT SHOP APOTHEKE EUROPE.
SHOP APOTHEKE EUROPE is the leading and fastest growing online pharmacy in
Continental Europe. With the acquisition of Europa Apotheek Venlo in
November 2017, SHOP APOTHEKE EUROPE significantly extended its European
market leadership with an expanded product range for the whole family in the
areas of OTC, beauty and care products as well as prescription drugs
SHOP APOTHEKE EUROPE already operates online pharmacies in Germany, Austria,
France, Belgium, Italy, Spain and the Netherlands. In Germany, the
TÜV-certified shop-apotheke.com is the market leader in terms of traffic.
SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original
products to about 2.7 million active customers quickly and at attractive
prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive and
consistent pharmaceutical services.
SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the
Frankfurt Stock Exchange (Prime Standard) since 13 October 2016.
MEDIA CONTACTS.
Trade and public media:
Sven Schirmer
Mobile: +49 152 28 50 63 61
Email: [email protected]
Financial media:
Thomas Schnorrenberg
Mobile: +49 151 46 53 13 17
Email: [email protected]
Investor Relations:
Dr. Ulrich Wandel
Telephone: +31 77 850 6117
Email: [email protected]
DISCLAIMER.
This publication is an advertisement.
This communication constitutes neither an offer to sell nor a solicitation
to buy securities of Shop Apotheke Europe N.V. in any jurisdiction. This is
not a securities prospectus. No public offering of any securities of Shop
Apotheke Europe N.V. is being made.
Statements contained herein may constitute "forward-looking statements."
Forward-looking statements are generally identifiable by the use of the
words "may", "will", "should", "plan", "expect", "anticipate", "estimate,"
"believe", "intend", "project", "goal" or "target" or the negative of these
words or other variations on these words or comparable terminology.
Forward-looking statements are based on current expectations and involve a
number of known and unknown risks, uncertainties and other factors that
could cause the Group's or its industry's actual results, levels of
activity, performance or achievements to be materially different from any
future results, levels of activity, performance or achievements expressed or
implied by such forward-looking statements. You should not place undue
reliance on forward-looking statements and the Group does not undertake
publicly to update or revise any forward-looking statement that may be made
herein, whether as a result of new information, future events or otherwise.
---------------------------------------------------------------------------
12.03.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: SHOP APOTHEKE EUROPE N.V.
Dirk Hartogweg 14
5928 LV Venlo
Netherlands
Phone: 0800 - 200 800 300
Fax: 0800 - 90 70 90 20
E-mail: [email protected]
Internet: www.shop-apotheke-europe.com
ISIN: NL0012044747
WKN: A2AR94
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
662507 12.03.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
SHOP APOTHEKE EUROPE N.V. ISIN: NL0012044747 können Sie bei EQS abrufen
E-Commerce , A2AR94 , RDC , XETR:RDC